471 related articles for article (PubMed ID: 11522180)
1. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
2. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
3. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
Shulman NS; Hughes MD; Winters MA; Shafer RW; Zolopa AR; Hellmann NS; Bates M; Whitcomb JM; Katzenstein DA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):121-7. PubMed ID: 12394789
[TBL] [Abstract][Full Text] [Related]
4. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
5. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
6. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
7. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
[TBL] [Abstract][Full Text] [Related]
9. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.
Shulman NS; Machekano RA; Shafer RW; Winters MA; Zolopa AR; Liou SH; Hughes M; Katzenstein DA;
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):377-80. PubMed ID: 11468426
[TBL] [Abstract][Full Text] [Related]
10. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Parikh UM; Bacheler L; Koontz D; Mellors JW
J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
[TBL] [Abstract][Full Text] [Related]
12. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
13. Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.
Matamoros T; Nevot M; Martínez MA; Menéndez-Arias L
J Biol Chem; 2009 Nov; 284(47):32792-802. PubMed ID: 19801659
[TBL] [Abstract][Full Text] [Related]
14. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
Kuritzkes DR; Bassett RL; Hazelwood JD; Barrett H; Rhodes RA; Young RK; Johnson VA;
J Acquir Immune Defic Syndr; 2004 May; 36(1):600-3. PubMed ID: 15097303
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Coakley EP; Gillis JM; Hammer SM
AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
[TBL] [Abstract][Full Text] [Related]
16. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
17. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
[TBL] [Abstract][Full Text] [Related]
18. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
[TBL] [Abstract][Full Text] [Related]
19. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
20. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):647-52. PubMed ID: 23061604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
